5-Chloropyridine-2-carbonitrile

We are 5-Chloropyridine-2-carbonitrile CAS:89809-64-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:5-Chloropyridine-2-carbonitrile
CAS.NO:89809-64-3
Synonyms:5-Chloropyridine-2-carbonitrile
5-Chloro-2-cyanopyridine
5-Chloro-2-pyridinecarbonitrile
 
Physical and Chemical Properties:
Density 1.3±0.1 g/cm3
Boiling Point 239.3±20.0 °C at 760 mmHg
Molecular Formula C6H3ClN2
Molecular Weight 138.554
Flash Point 98.5±21.8 °C
 
Specification:
Appearance:White to yellow or brown crystalline powder
Assay:≥97.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate

5-Chloropyridine-2-carbonitrile


Related News: With nearly 194 billion US dollars of original research medicines facing the expiration of patents in the past five years, more and more domestic companies are focusing on the corresponding characteristic APIs, and have started research and development and production preparations in advance. The scale of production and export of APIs will continue to expand and grow.216854-23-8 The first is the API – which is the central ingredient.methyl 3-(2-methoxy-5-methylphenyl)-3-phenylpropanoate Biogen last month revived its plans to seek U.S. approval for its aducanumab treatment after announcing in March that it would terminate two large clinical trials for the drug. But some analysts believed FDA approval is highly unlikely.1,3,5-Tri-O-Benzoyl-2-Deoxy-2-Fluoro -α-D-Arabinose CAS:97614-43-2 Biogen last month revived its plans to seek U.S. approval for its aducanumab treatment after announcing in March that it would terminate two large clinical trials for the drug. But some analysts believed FDA approval is highly unlikely.INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment.

Related Products
Product Name
10-Methoxy-4H-benzo[4,5]cyclohepta[1,2-b]thiophen-4-one View Details
1-Bromo-3-methylbutane View Details
2-bromo-6-(trifluoromethyl)aniline View Details
2-phenylethylamine manufacturer 3-Nitrobenzotrifluoride manufacturer 5-Fluoro-2-methylindole manufacturer 3-Ethyl-4-methyl-3-pyrrolin-2-one manufacturer 4-Aminobenzotrifluoride manufacturer